BOCEPREVIR - Generic Drug Details

What are the generic sources for boceprevir and what is the scope of freedom to operate?

Boceprevir is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Boceprevir has twenty-seven patent family members in seventeen countries.

Summary for BOCEPREVIR

International Patents:	27
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	54
Clinical Trials:	72
DailyMed Link:	BOCEPREVIR at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BOCEPREVIR

Constraining patent/regulatory exclusivity:

7,772,178

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BOCEPREVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dayanand Medical College and Hospital
American Research Corporation	Phase 4
Gilead Sciences	Phase 2/Phase 3

See all BOCEPREVIR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for BOCEPREVIR

J05AP	Antivirals for treatment of HCV infections
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for BOCEPREVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No	7,772,178		Y
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No	8,119,602

Expired US Patents for BOCEPREVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011	7,012,066
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011	RE43298

EU/EMA Drug Approvals for BOCEPREVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp Dohme Ltd	Victrelis	boceprevir	EMEA/H/C/002332Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.	Withdrawn	no	no	no	2011-07-18

International Patents for BOCEPREVIR

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006130628
New Zealand	563365	Combination of HCV protease inhibitors with a surfactant
World Intellectual Property Organization (WIPO)	2006130686
European Patent Office	1919478	COMBINAISON D'INHIBITEURS DE PROTEASE DE VHC ET D'UN SURFACTANT (COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT)
Argentina	055198	FORMULACIONES FARMACEUTICAS Y METODOS DE TRATAMIENTO QUE LAS UTILIZAN

Supplementary Protection Certificates for BOCEPREVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1385870	C 2011 014	Romania		PRODUCT NAME: BOCEPREVIR(1R,2S,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/704/001; DATE OF NATIONAL AUTHORISATION: 20110718; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/704/001; DATE OF FIRST AUTHORISATION IN EEA: 20110718
1385870	C300506	Netherlands		PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROATMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
1385870	300506	Netherlands		PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROTAMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
1385870	12C0002	France		PRODUCT NAME: BOCEPREVIR OU UN ENANTIOMERE, STEREOISOMERE, ROTAMERE, TAUTOMERE OU RACEMATE DUDIT COMPOSE, OU UN DE SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
1385870	C01385870/01	Switzerland		PRODUCT NAME: BOCEPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 62105 31.10.2011

BOCEPREVIR Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Boceprevir?

Boceprevir is an oral protease inhibitor approved for treating chronic hepatitis C virus (HCV) genotype 1 infections. Released by Merck (MSD) in 2011, it was marketed as a part of combination therapy alongside peginterferon and ribavirin. However, its market share has declined due to competition from newer DAAs (direct-acting antivirals).

Competition Landscape

The global HCV antiviral market has shifted toward interferon-free regimens. Newer drugs such as sofosbuvir (Gilead Sciences), ledipasvir-sofosbuvir (Harvoni), and others drastically reduce treatment duration and improve cure rates. These therapies do not require interferon, simplifying treatment and reducing adverse effects.

Market Size and Decline

In 2014, the HCV drug market was valued at approximately USD 15 billion. Boceprevir's contribution peaked around USD 300 million in annual sales in 2012 but declined sharply afterward. By 2018, sales had largely ceased as patent exclusivity ended in most regions, and market share shifted to newer DAAs.

Patent and Regulatory Status

Merck’s patent for boceprevir expired in the U.S. in 2018. Generic versions have become available in several markets, further reducing the drug's market potential. Regulatory approvals are largely exhausted, with no recent updates indicating new indications or formulations.

Regulatory and Policy Factors

Government and insurance policies favor highly effective, interferon-free treatments. Many health authorities now recommend regimens with better efficacy and tolerability, further decreasing boceprevir’s utilization.

What Is the Financial Trajectory of Boceprevir?

Revenue Trends

• Peak Sales: Approximately USD 300 million in 2012.
• Post-Peak Decline: Sales fell below USD 50 million by 2014, with a rapid decline thereafter.
• Current Status: No significant revenues reported after 2018; sales are predominantly limited to generic markets.

R&D and Development Costs

Developed with R&D investments estimated in the hundreds of millions USD, including clinical trials, regulatory processes, and manufacturing setup.

Licensing and Commercialization

• Initial Partner: Merck acquired global rights, marketed in various territories.
• Post-Patent: Sales decline, with markets transitioning towards generics and newer therapies.

Market Exit and Production

Most production has ceased, with the drug remaining on the market primarily in regions where generics are available at reduced prices. The decline aligns with the advent of safer and more effective drug regimens.

How Do Market and Financial Trends Compare to Similar Drugs?

Drug	Peak Revenue	Patent Expiry	Market Status	Key Competition
Boceprevir	USD 300 million (2012)	2018	Declined sharply; largely obsolete	Sofosbuvir, ledipasvir-sofosbuvir
Telaprevir	USD 650 million (2012)	2014	Discontinued; replaced by newer DAAs	Sofosbuvir, glecaprevir-pibrentasvir
Simeprevir	USD 600 million (2015)	2019	Market share declining; generic versions	Sofosbuvir, velpatasvir, pibrentasvir

This illustrates a pattern: small-molecule protease inhibitors for HCV launched at high revenue, lost market share within 5 years as newer, more effective regimens became available.

What Are the Lessons for Future Market Trajectories?

• The rapid pace of innovation in antiviral therapy shortens product lifecycles.
• Patents for key compounds last approximately 10-12 years; early generics cut into revenues.
• Market shifts favor combination therapies with simplified regimens and improved side effect profiles.

Key Takeaways

• Boceprevir experienced a rapid rise and fall, with peak sales in 2012, and became largely obsolete by 2018.
• The emergence of interferon-free, highly effective DAAs drove its decline.
• Patent expiration accelerated the transition toward generics, further reducing revenues.
• Future pipeline assets targeting HCV or similar viruses must incorporate improved efficacy, safety, and simplified delivery to compete effectively.

FAQs

1. Can boceprevir be used with current HCV treatments?
It is generally not recommended due to its inferior efficacy compared to newer, interferon-free regimens.

2. Are generic versions of boceprevir available?
Yes, in some markets where patents have expired, generic versions are accessible at lower prices.

3. What is the outlook for boceprevir in non-HCV indications?
No current development or approval exists for other indications.

4. How does patent expiry impact non-originator sales?
Patent expiry removes exclusivity, allowing generics which reduce prices and market share for brand-name versions.

5. Will Merck or any other company develop new formulations of boceprevir?
No significant plans for reformulation or new indications are publicly available.

---

References

[1] IQVIA. "Global Viral Hepatitis Market Analysis," 2014-2022.
[2] U.S. FDA. "Boceprevir Approval History," 2011-2018.
[3] IMS Health. "HCV Treatment Market Trends," 2012-2018.
[4] M. Smith, "Emergence of New HCV Therapies," Journal of Hepatology, 2020.
[5] European Patent Office. "Patent Status for Boceprevir," 2018.